Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 67,612 | 93,510 | 109,966 | 81,051 | 52,386 |
| Marketable Securities | 442,341 | 427,034 | 264,915 | 276,774 | 315,188 |
| Receivables | N/A | N/A | 15,000 | N/A | N/A |
| Other current assets | 1,704 | 2,030 | 3,762 | 3,778 | 4,122 |
| TOTAL | $525,407 | $537,253 | $405,317 | $375,694 | $385,402 |
| Non-Current Assets | |||||
| PPE Net | 51,735 | 49,336 | 48,134 | 36,145 | 27,494 |
| Investments And Advances | 192,445 | 224,390 | 61,434 | 76,988 | 104,759 |
| Other Non-Current Assets | 56,434 | 57,272 | 60,874 | 63,551 | 64,290 |
| TOTAL | $300,614 | $330,998 | $170,442 | $176,684 | $196,543 |
| Total Assets | $826,021 | $868,251 | $575,759 | $552,378 | $581,945 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,510 | 6,812 | 7,075 | 4,978 | 3,745 |
| Accrued Expenses | 23,780 | 15,997 | 33,864 | 26,383 | 22,490 |
| Other current liabilities | 178 | 824 | 524 | 858 | 268 |
| TOTAL | $62,143 | $56,136 | $85,691 | $63,166 | $54,602 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 19,259 | 22,613 | 37,883 | 27,352 | 24,302 |
| Other Non-Current Liabilities | 74,822 | 75,975 | 77,028 | 76,613 | 70,732 |
| TOTAL | $78,954 | $100,912 | $95,097 | $93,677 | $91,915 |
| Total Liabilities | $141,097 | $157,048 | $180,788 | $156,843 | $146,517 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 61,753 | 61,358 | 61,112 | 55,487 | 55,412 |
| Common Shares | 6 | 6 | 6 | 6 | 6 |
| Retained earnings | -621,371 | -579,309 | -530,752 | -516,384 | -463,517 |
| Other shareholders' equity | -2,099 | -1,777 | -552 | -2,450 | -3,635 |
| TOTAL | $684,924 | $711,203 | $394,971 | $395,535 | $435,428 |
| Total Liabilities And Equity | $826,021 | $868,251 | $575,759 | $552,378 | $581,945 |